Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quadrivalent influenza mRNA vaccine MRT5410
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Quadrivalent influenza mRNA vaccine MRT5410 is an investigational messenger RNA (mRNA) vaccine designed to protect against four strains of the influenza virus. The vaccine uses mRNA technology to encode antigens from these strains, prompting the body’s cells to produce viral proteins that stimulate an immune response. This approach aims to induce both humoral and robust T-cell immunity against seasonal flu viruses. The formulation typically involves encapsulating the mRNA in lipid nanoparticles for delivery and stability. Developed by Sanofi, this candidate is being evaluated for safety and immunogenicity in adults aged 18 years and older[2][3][5]. As of early 2024, it is undergoing Phase 1/Phase 2 clinical trials.
- Other names
- quadrivalent influenza mRNA vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on Quadrivalent influenza mRNA vaccine MRT5410.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quadrivalent influenza mRNA vaccine MRT5410.